NCT02919683View on ClinicalTrials.gov

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

December 31, 2025

Conditions

Head and Neck Cancer

Interventions

DRUG

Nivolumab

DRUG

Ipilimumab

PROCEDURE

Standard of Care Surgery

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02919683 - Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity | Biotech Hunter | Biotech Hunter